Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is a China-based clinical-stage biotechnology company specializing in the discovery, development, and commercialization of innovative immunotherapies for cancers and autoimmune diseases. The company leverages its proprietary VersatiBody platform to advance a diversified pipeline, with lead candidate HX009, a bifunctional anti-PD-1/SIRPα antibody fusion protein designed to enhance immune response against tumors, currently in Phase 2 trials for advanced solid neoplasms. Key products also include HX301, a multi-targeted kinase inhibitor; HX044, a bispecific antibody targeting CD47 and CTLA4 for PD-1-resistant solid tumors in Phase 1/2; and HX008, a PD-1 antagonist monoclonal antibody. Focused on immuno-oncology pathways, Hanx Biopharmaceuticals employs monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates to address unmet needs in oncology and immunology. Founded in 2014 and headquartered in Wuhan, the firm plays a role in advancing next-generation precision therapies within the global biotechnology sector.